- Home
- FRSH vs PCVX Comparison
FRSH vs PCVX Comparison
Compare FRSH & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRSH
- PCVX
- Stock Information
- Founded
- FRSH 2010
- PCVX 2013
- Country
- FRSH United States
- PCVX United States
- Employees
- FRSH N/A
- PCVX N/A
- Industry
- FRSH EDP Services
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- FRSH Technology
- PCVX Health Care
- Exchange
- FRSH Nasdaq
- PCVX Nasdaq
- Market Cap
- FRSH 3.7B
- PCVX 4.0B
- IPO Year
- FRSH 2021
- PCVX 2020
- Fundamental
- Price
- FRSH $11.65
- PCVX $45.43
- Analyst Decision
- FRSH Buy
- PCVX Strong Buy
- Analyst Count
- FRSH 16
- PCVX 7
- Target Price
- FRSH $19.44
- PCVX $101.67
- AVG Volume (30 Days)
- FRSH 3.6M
- PCVX 1.4M
- Earning Date
- FRSH 11-05-2025
- PCVX 11-04-2025
- Dividend Yield
- FRSH N/A
- PCVX N/A
- EPS Growth
- FRSH N/A
- PCVX N/A
- EPS
- FRSH N/A
- PCVX N/A
- Revenue
- FRSH $810,640,000.00
- PCVX N/A
- Revenue This Year
- FRSH $17.01
- PCVX N/A
- Revenue Next Year
- FRSH $13.02
- PCVX N/A
- P/E Ratio
- FRSH N/A
- PCVX N/A
- Revenue Growth
- FRSH 18.18
- PCVX N/A
- 52 Week Low
- FRSH $10.51
- PCVX $27.66
- 52 Week High
- FRSH $19.77
- PCVX $107.22
- Technical
- Relative Strength Index (RSI)
- FRSH 55.52
- PCVX 61.99
- Support Level
- FRSH $10.52
- PCVX $40.14
- Resistance Level
- FRSH $11.31
- PCVX $45.90
- Average True Range (ATR)
- FRSH 0.35
- PCVX 2.14
- MACD
- FRSH 0.09
- PCVX -0.28
- Stochastic Oscillator
- FRSH 98.25
- PCVX 90.21
About FRSH Freshworks Inc.
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.